SShots:The P-IV (PEARL) study (N=1140) evaluating fremanezumab met its 1EP and 2EPs, demonstrating long-term effectiveness over two years, significantly reducing the frequency, duration, and severity of migraine attacks in both chronic and episodic migraine ptsThe study met 1EP of ≥50% reduction in MMD within the first 6mos. of treatment. Injection adherence remained high…